The South & Central America epilepsy drugs market was valued at US$ 458.85 million in 2022 and is expected to reach US$ 585.38 million by 2030; it is estimated to grow at a CAGR of 3.1% from 2022 to 2030.
Several Epilepsy Drugs Nearing Patent Expiration Fuels South & Central America Epilepsy Drugs Market
Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.
|
Company |
Patent |
Patent Expiration Date |
Ingredient |
Treatment |
|
Sumitomo Pharma Co |
US9206135 |
April 21, 2026 |
ESLICARBAZEPINE ACETATE |
Partial-onset Seizures Epilepsy |
|
GlaxoSmithKline |
US7919115 |
January 4, 2029 |
LAMOTRIGINE |
Epilepsy |
|
Ucb Inc |
USRE38551 |
March 17, 2022 |
Lacosamide |
Epilepsy and Partial-onset Seizures |
|
SK Biopharmaceuticals |
US7598279 |
October 30, 2027 |
CENOBAMATE |
Partial Epilepsies |
|
SUPERNUS PHARMS |
US8877248 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US9555004 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US10314790 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US8663683 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US9622983 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US8298580 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US8992989 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US8889191 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US9549940 |
November, 2027 |
Sustained-release formulations of Topiramate |
Epilepsy |
|
SUPERNUS PHARMS |
US8298576 |
April, 2028 |
Sustained-release formulations of Topiramate |
Epilepsy |
South & Central America Epilepsy Drugs Market Overview
The South & Central America epilepsy drugs market is segmented into the Brazil, Argentina, and the Rest of South & central America. The market growth in this region is attributed due to the rise in number of people affected with epilepsy, growing aging population, ongoing R&D in the field of epilepsy drugs in the region, growing regulatory approvals for new product, and rise in number of accidents and brain injuries in epilepsy drugs.
South & Central America Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Epilepsy Drugs Market Segmentation
The South & Central America epilepsy drugs market is segmented into treatment, distribution channel, and country.
Based on treatment, the South & Central America epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.
In terms of distribution channel, the South & Central America epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.
Based on country, the South & Central America epilepsy drugs market is segmented Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America epilepsy drugs market in 2022.
Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, and UCB SA are some of the leading companies operating in the South & Central America epilepsy drugs market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 458.85 Million |
| Market Size by 2030 | US$ 585.38 Million |
| CAGR (2022 - 2030) | 3.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment
|
|
Regions and Countries Covered
|
|
| South and Central America | Brazil, Argentina, Rest of South and Central America |
| Market leaders and key company profiles |
|
1. Abbott Laboratories
2. Alkem Laboratories Ltd
3. GSK Plc
4. Novartis AG
5. Pfizer Inc
6. Sanofi SA
7. Teva Pharmaceutical Industries Ltd
The South & Central America Epilepsy Drugs Market is valued at US$ 458.85 Million in 2022, it is projected to reach US$ 585.38 Million by 2030.
As per our report South & Central America Epilepsy Drugs Market, the market size is valued at US$ 458.85 Million in 2022, projecting it to reach US$ 585.38 Million by 2030. This translates to a CAGR of approximately 3.1% during the forecast period.
The South & Central America Epilepsy Drugs Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Epilepsy Drugs Market report:
The South & Central America Epilepsy Drugs Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Epilepsy Drugs Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Epilepsy Drugs Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For South & Central America Epilepsy Drugs Market
